Astrana Health Inc.

Greetings. Welcome to Powell Medical Holdings' third quarter 2021 financial results call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If you'd like to ask a question at that time, please press star 1 on your telephone keypad, and a confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. If anyone today should require operator assistance during the call, please press star zero from your telephone keypad. Please note this conference is being recorded. At this time, I'll turn the conference over to Caroline Tso with Investor Relations. Caroline, you may begin.

Thank you, Operator, and hello, everyone. Thank you for joining us. The press release announcing Apollo Medical Holdings, Inc.'s results for the third quarter ended September 30, 2021 is available at the Investors section of the company's website at www.apollo.com. To provide some additional background on its results, the company has made a supplemental deck available on its website. A replay of this broadcast will also be made available at ApolloMed's website after the conclusion of this call. Before we get started, I would like to remind everyone that this conference call and any accompanying information discussed herein contains certain forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terms such as anticipate, believe, expect, future, plan, outlook, and will, and include, among other things, statements regarding the company's guidance for the year ending December 31, 2021, continued growth, acquisition strategy, ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, Strategic growth plans and merger integration efforts as well as the impact of the 2020 novel coronavirus or COVID-19 pandemic and the Delta variant on the company's business, operations, and financial results. Additionally, certain financial measures we will discuss on this call are non-GAAP financial measures. We believe that providing these measures helps investors gain a better and more complete understanding of our financial results and is consistent with how management views our financial results. A reconciliation of these non-GAAP measures to the most comparable GAAP measure is available in the earnings press release and Form 8-K filed with the SEC. Although the company believes that the expectations reflected in its forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties that could cause the actual results to differ dramatically from those projected. There can be no assurance that those expectations will prove to be correct. Information about the risk associated with investing in ApolloMed is included in its filings with the Securities and Exchange Commission, which we encourage you to review before making an investment decision. The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions, or otherwise, except as required by law. Regarding the disclaimer language, I would also like to refer you to slide two of the conference call presentation for further information. For those of you following along with the accompanying supplement, there is an overview of the company on slide three. On today's call, the company's executive chairman, Dr. Kenneth Sim, will make some opening remarks and then turn the call over to Brandon Sim, the company's co-CEO, who will discuss the third quarter and year-to-date 2021 highlights and the latest operational developments. Chief Financial Officer Eric Chin will follow with a review of Parliament's results for the third quarter and first nine months of 2021. Brandon will conclude the remarks with an update on the company's outlook and long-term growth strategy before opening the floor for questions. With that, I'll turn the call over to Apollo Med's Executive Chairman, Dr. Kenneth Sim. Please go ahead, Dr. Sim.

Good afternoon to all of you, and thank you for joining us to discuss Apollo Med's third quarter 2021 results. I would like to begin this call by addressing the leadership changes we announced. in conjunction with our earnings report this afternoon. We are very pleased to appoint Brandon Sim as Apollo Med's co-CEO, effective November the 2nd. Since joining the company, Brandon has led key efforts in creating and executing Apollo Med's new growth model, navigating the COVID-19 global pandemic and transforming have all met into the technology-powered healthcare company that it is today. As Chief Technology Officer, Brandon built a team of engineers and data scientists from the ground up over the last two and a half years, leading the development of ApolloMed's proprietary technology platform. This platform serves as a operating system for value-based care has allowed the company to scale effectively across local healthcare delivery systems, greatly reducing operating expenses and leading to notable financial performance improvements. More importantly, this platform is helping us drive improved clinical outcomes and patient satisfaction by streamlining care and utilization management workflows. The platform also algorithmically services actionable data and insights so that our providers can take on and succeed in value-based care arrangements. As Chief Operating Officer, Brandon has spearheaded ApolloMet's corporate strategy, business development, operations, and engineering efforts for over a year now, and he will continue to lead those efforts as co-CEO. I will continue to serve as executive chairman of the board, working closely with the board of directors and executive management team. ApolloMed has been evolving towards becoming a technology-powered, integrated healthcare delivery company for the last few years. As this leadership transition marks a major milestone in our continued efforts to provide Patients with best-in-class valued-based care. Having witnessed the incredible results yielded by Brandon's passion and drive, the Board of Directors and I are confident that Brandon is the right person to lead Apollo Med into its next chapter. It is truly an incredibly exciting time at our company, and we look forward to continuing our success and rapid growth under Brandon's leadership. With that, I would like to turn it over to Brandon, who will go over highlights for the third quarter and year-to-date 2021, as well as recent operational developments. Now, Brandon.